Interferon α may be back on track to treat acute myeloid leukemia

Our own experience and a thorough literature review suggest that interferon α (IFNα) should be reconsidered for the treatment of acute myeloid leukemia patients. Most likely, the success of such treatment depends on the achievement of high serum levels of IFNα for several months, which can be obtain...

Descripción completa

Detalles Bibliográficos
Autores principales: Smits, Evelien L.J.M., Anguille, Sébastien, Berneman, Zwi N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654584/
https://www.ncbi.nlm.nih.gov/pubmed/23734314
http://dx.doi.org/10.4161/onci.23619
_version_ 1782269585180852224
author Smits, Evelien L.J.M.
Anguille, Sébastien
Berneman, Zwi N.
author_facet Smits, Evelien L.J.M.
Anguille, Sébastien
Berneman, Zwi N.
author_sort Smits, Evelien L.J.M.
collection PubMed
description Our own experience and a thorough literature review suggest that interferon α (IFNα) should be reconsidered for the treatment of acute myeloid leukemia patients. Most likely, the success of such treatment depends on the achievement of high serum levels of IFNα for several months, which can be obtained by using pegylated IFNα.
format Online
Article
Text
id pubmed-3654584
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36545842013-06-03 Interferon α may be back on track to treat acute myeloid leukemia Smits, Evelien L.J.M. Anguille, Sébastien Berneman, Zwi N. Oncoimmunology Author's View Our own experience and a thorough literature review suggest that interferon α (IFNα) should be reconsidered for the treatment of acute myeloid leukemia patients. Most likely, the success of such treatment depends on the achievement of high serum levels of IFNα for several months, which can be obtained by using pegylated IFNα. Landes Bioscience 2013-04-01 2013-04-01 /pmc/articles/PMC3654584/ /pubmed/23734314 http://dx.doi.org/10.4161/onci.23619 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Smits, Evelien L.J.M.
Anguille, Sébastien
Berneman, Zwi N.
Interferon α may be back on track to treat acute myeloid leukemia
title Interferon α may be back on track to treat acute myeloid leukemia
title_full Interferon α may be back on track to treat acute myeloid leukemia
title_fullStr Interferon α may be back on track to treat acute myeloid leukemia
title_full_unstemmed Interferon α may be back on track to treat acute myeloid leukemia
title_short Interferon α may be back on track to treat acute myeloid leukemia
title_sort interferon α may be back on track to treat acute myeloid leukemia
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654584/
https://www.ncbi.nlm.nih.gov/pubmed/23734314
http://dx.doi.org/10.4161/onci.23619
work_keys_str_mv AT smitsevelienljm interferonamaybebackontracktotreatacutemyeloidleukemia
AT anguillesebastien interferonamaybebackontracktotreatacutemyeloidleukemia
AT bernemanzwin interferonamaybebackontracktotreatacutemyeloidleukemia

Ejemplares similares